Production (Stage)
Ovid Therapeutics Inc.
OVID
$0.3186
$0.00531.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 548.00K | 566.00K | 632.00K | 568.00K | 474.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 548.00K | 566.00K | 632.00K | 568.00K | 474.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 548.00K | 566.00K | 632.00K | 568.00K | 474.00K |
| SG&A Expenses | 24.64M | 25.79M | 25.20M | 26.47M | 27.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.96M | 60.85M | 66.48M | 65.22M | 59.58M |
| Operating Income | -55.42M | -60.28M | -65.85M | -64.65M | -59.11M |
| Income Before Tax | -24.97M | -26.43M | -32.50M | -29.75M | -50.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.97 | -26.43 | -32.50 | -29.75 | -50.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.97M | -26.43M | -32.50M | -29.75M | -50.68M |
| EBIT | -55.42M | -60.28M | -65.85M | -64.65M | -59.11M |
| EBITDA | -54.80M | -59.67M | -65.26M | -64.08M | -58.55M |
| EPS Basic | -0.34 | -0.37 | -0.45 | -0.41 | -0.70 |
| Normalized Basic EPS | -0.22 | -0.25 | -0.31 | -0.28 | -0.47 |
| EPS Diluted | -0.35 | -0.37 | -0.46 | -0.42 | -0.71 |
| Normalized Diluted EPS | -0.22 | -0.26 | -0.31 | -0.28 | -0.47 |
| Average Basic Shares Outstanding | 283.95M | 283.62M | 283.30M | 282.94M | 282.56M |
| Average Diluted Shares Outstanding | 284.23M | 283.90M | 283.58M | 283.22M | 282.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |